Sexual networks and the transmission of drug-resistant HIV

Current Opinion in Infectious Diseases

Volumn 21, Issue 6, 2008, Pages 644-652

  Drumright, Lydia N ^a   Frost, Simon D W ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

HIV; Molecular epidemiology; Primary infection; Sexual network; Transmitted drug resistance

Indexed keywords

RNA DIRECTED DNA POLYMERASE INHIBITOR;

DEMOGRAPHY; DRUG EFFICACY; ECOLOGY; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; PHYLOGENY; PREDICTION; REVIEW; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; SUBSTANCE ABUSE;

DRUG RESISTANCE, VIRAL; GENOTYPE; HIV; HIV INFECTIONS; HUMANS; RNA, VIRAL; SEXUAL BEHAVIOR;

EID: 57049161939     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328318977c     Document Type: Review

References (166)

1. Gómez-Cano M, Rubio A, Puig T, et al. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. AIDS 1998; 12:1015-1020.
2. Puig T, Pérez-Olmeda M, Rubio A, et al. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. The ERASE-2 Study Group. AIDS 2000; 14:727-732.
3. Gallego O, Ruiz L, Vallejo A, et al. Changes in the rate of genotypic resistance to antiretroviral drugs in Spain. AIDS 2001; 15:1894-1896.
4. Tamalet C, Fantini J, Tourres C, Yahi N. Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes. AIDS 2003; 17:2383-2388.
5. Richman DD, Morton SC, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004; 18:1393-1401.
6. Scott P, Arnold E, Evans B, et al. Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000. J Antimicrob Chemother 2004; 53:469-473.
7. Costagliola D, Descamps D, Assoumou L, et al. Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study. J Acquir Immune Defic Syndr 2007; 46:12-18.
8. de Mendoza C, Garrido C, Corral A, et al. Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients. AIDS Res Hum Retroviruses 2007; 23:879-885.
9. Kozal MJ, Amico KR, Chiarella J, et al. Antiretroviral resistance and high-risk transmission behavior among HIV-positive patients in clinical care. AIDS 2004; 18:2185-2189.
10. Chin-Hong PV, Deeks SG, Liegler T, et al. High-risk sexual behavior in adults with genotypically proven antiretroviral-resistant HIV infection. J Acquir Immune Defic Syndr 2005; 40:463-471.
11. Kozal MJ, Amico KR, Chiarella J, et al. A population-based and longitudinal study of sexual behavior and multidrug-resistant HIV among patients in clinical care. MedGenMed 2006; 8:72.
12. Erice A, Mayers DL, Strike DG, et al. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med 1993; 328:1163-1165.
13. Hermans P, Sprecher S, Clumeck N. Primary infection with zidovudine-resistant HIV. N Engl J Med 1993; 329:1123; author reply 1124.
14. Masquelier B, Lemoigne E, Pellegrin I, et al. Primary infection with zidovudine-resistant HIV. N Engl J Med 1993; 329:1123-1124.
15. Sönnerburg A, Johansson B, Ayehunie S, Julander I. Transmission of zidovudine-resistant HIV-1. AIDS 1993; 7:1684-1685.
16. Angarano G, Monno L, Appice A, et al. Transmission of zidovudine-resistant HIV-1 through heterosexual contacts. AIDS 1994; 8:1013-1014.
17. Kuritzkes DR, Bell S, Bakhtiari M. Rapid CD4+ cell decline after sexual transmission of a zidovudine-resistant syncytium-inducing isolate of HIV-1. AIDS 1994; 8:1017-1019.
18. Conlon CP, Klenerman P, Edwards A, et al. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. J Infect Dis 1994; 169:411-415.
19. Imrie A, Beveridge A, Genn W, et al. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group. J Infect Dis 1997; 175:1502-1506.
20. Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998; 339:307-311.
21. Mohri H, Singh MK, Ching WT, Ho DD. Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients. Proc Natl Acad Sci U S A 1993; 90:25-29.
22. de Ronde A, Schuurman R, Goudsmit J, et al. First case of new infection with zidovudine-resistant HIV-1 among prospectively studied intravenous drug users and homosexual men in Amsterdam, The Netherlands. AIDS 1996; 10:231-232.
23. Yerly S, Rakik A, de Loes SK, et al. Prevalence of transmission of zidovudine-resistant viruses in Switzerland. l'Etude suisse de cohorte VIH. Schweiz Med Wochenschr 1996; 126:1845-1848.
24. Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999; 282:1135-1141.
25. Césaire R, Santos GD, Abel S, et al. Drug resistance mutations among HIV-1 strains from antiretroviral-naive patients in Martinique, French West Indies. J Acquir Immune Defic Syndr 1999; 22:401-405.
26. Little SJ, Daar ES, D'Aquila RT, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 1999; 282:1142-1149.
27. Balotta C, Berlusconi A, Pan A, et al. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and preexisting mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals. Antivir Ther 2000; 5:7-14.
28. Brenner B, Weinberg MA, Salomon H, et al. Resistance to antiretroviral drugs in patients with primary HIV-1 infection. Investigators of the Quebec Primary Infection Study. Int J Antimicrob Agents 2000; 16:429-434.
29. Kindelán JM, Giménez-Doménech R, Vidal-Verdú E, Madueño J. Prevalence of primary mutations in human immunodeficiency virus with resistance to nucleoside analogues in previously untreated patients from Andalusia. Andalusian Group for the Study of Infectious diseases (GAEI). Med Clin (Barc) 2000; 115:423-425.
30. Salomon H, Weinberg MA, Brenner B, et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS 2000; 14:F17-F23.
31. Tamalet C, Pasquier C, Yahi N, et al. Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV-1 infection. J Med Virol 2000; 61:181-186.
32. Trabaud MA, Leriche-Guerin K, Regis C, et al. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus. J Med Virol 2000; 61:352-359.
33. Wegner SA, Brodine SK, Mascola JR, et al. Prevalence of genotypic and phenotypic resistance to antiretroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel. AIDS 2000; 14:1009-1015.
34. Briones C, Pérez-Olmeda M, Rodríguez C, et al. Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid. J Acquir Immune Defic Syndr 2001; 26:145-150.
35. Pérez-Olmeda M, Romero JD, Rubio A, et al. Primary HIV-1 drug resistance in Spain before and after the introduction of protease inhibitors. J Med Virol 2001; 63:85-87.
36. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288:181-188.
37. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-394.
38. Simon V, Vanderhoeven J, Hurley A, et al. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 2002; 16:1511-1519.
39. Violin M, Forbici F, Cozzi-Lepri A, et al. Primary HIV-1 resistance in recently and chronically infected individuals of the Italian Cohort Naive for Antiretrovirals. J Biol Regul Homeost Agents 2002; 16:37-43.
40. Hanna GJ, Balaguera HU, Freedberg KA, et al. Drug-selected resistance mutations and non-B subtypes in antiretroviral-naive adults with established human immunodeficiency virus infection. J Infect Dis 2003; 188:986-991.
41. Maljkovic I, Wilbe K, Sölver E, et al. Limited transmission of drug-resistant HIV type 1 in 100 Swedish newly detected and drug-naive patients infected with subtypes A, B, C, D, G, U, and CRF01_AE. AIDS Res Hum Retroviruses 2003; 19:989-997.
42. Park SW, Kim HB, Choi YJ, et al. Genotypic resistance of antiretroviral drugs among drug-naive HIV type 1 patients with the background of long-term access-easy zidovudine therapy. AIDS Res Hum Retroviruses 2003; 19:1039-1043.
43. Zhong P, Kang L, Pan Q, et al. Identification and distribution of HIV type 1 genetic diversity and protease inhibitor resistance-associated mutations in Shanghai, P. R. China. J Acquir Immune Defic Syndr 2003; 34:91-101.
44. Weinstock HS, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004; 189:2174-2180.
45. Descamps D, Chaix ML, André P, et al. French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr 2005; 38:545-552.
46. Escoto-Delgadillo M, Vázquez-Valls E, Ramirez-Rodríguez M, et al. Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico. HIV Med 2005; 6:403-409.
47. Masquelier B, Bhaskaran K, Pillay D, et al. Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003. J Acquir Immune Defic Syndr 2005; 40:505-511.
48. Novak RM, Chen L, MacArthur RD, et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis 2005; 40:468-474.
49. de Parga EV, Rakhmanova A, Pérez-Alvarez L, et al. Analysis of drug resistance-associated mutations in treatment-naïve individuals infected with different genetic forms of HIV-1 circulating in countries of the former Soviet Union. J Med Virol 2005; 77:337-344.
50. Babic DZ, Zelnikar M, Seme K, et al. Prevalence of antiretroviral drug resistance mutations and HIV-1 non-B subtypes in newly diagnosed drug-naïve patients in Slovenia, 2000-2004. Virus Res 2006; 118:156-163.
51. Barreto CC, Nishyia A, Araújo LV, et al. Trends in antiretroviral drug resistance and clade distributions among HIV-1-infected blood donors in Sao Paulo, Brazil. J Acquir Immune Defic Syndr 2006; 41:338-341.
52. Jayaraman GC, Archibald CP, Kim J, et al. A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: results from the Canadian HIV strain and drug resistance surveillance program. J Acquir Immune Defic Syndr 2006; 42:86-90.
53. Koizumi Y, Ndembi N, Miyashita M, et al. Emergence of antiretroviral therapy resistance-associated primary mutations among drug-naive HIV-1-infected individuals in rural western Cameroon. J Acquir Immune Defic Syndr 2006; 43:15-22.
54. Lama JR, Sanchez J, Suarez L, et al. Linking HIV and antiretroviral drug resistance surveillance in Peru: a model for a third-generation HIV sentinel surveillance. J Acquir Immune Defic Syndr 2006; 42:501-505.
55. Petroni A, Deluchi G, Pryluka D, et al. Update on primary HIV-1 resistance in Argentina: emergence of mutations conferring high-level resistance to non-nucleoside reverse transcriptase inhibitors in drug-naive patients. J Acquir Immune Defic Syndr 2006; 42:506-510.
56. Rodrigues R, Scherer LC, Oliveira CM, et al. Low prevalence of primary antiretroviral resistance mutations and predominance of HIV-1 clade C at polymerase gene in newly diagnosed individuals from south Brazil. Virus Res 2006; 116:201-207.
57. Shet A, Berry L, Mohri H, et al. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J Acquir Immune Defic Syndr 2006; 41:439-446.
58. Tee KK, Kamarulzaman A, Ng KP. Short communication: low prevalence of genotypic drug resistance mutations among antiretroviral-naive HIV type 1 patients in Malaysia. AIDS Res Hum Retroviruses 2006; 22:121-124.
59. Teixeira SLM, Bastos FI, Hacker MA, et al. Trends in drug resistance mutations in antiretroviral-naïve intravenous drug users of Rio de Janeiro. J Med Virol 2006; 78:764-769.
60. Vergne L, Diagbouga S, Kouanfack C, et al. HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon. Antivir Ther 2006; 11:575-579.
61. Vessière A, Nerrienet E, Kfutwah A, et al. HIV-1 pol gene polymorphism and antiretroviral resistance mutations in drug-naive pregnant women in Yaoundé, Cameroon. J Acquir Immune Defic Syndr 2006; 42:256-258.
62. Vidal N, Mulanga C, Bazepeo SE, et al. HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in the Democratic Republic of Congo (DRC). AIDS Res Hum Retroviruses 2006; 22:202-206.
63. Zarandia M, Tsertsvadze T, Carr JK, et al. HIV-1 genetic diversity and genotypic drug susceptibility in the Republic of Georgia. AIDS Res Hum Retroviruses 2006; 22:470-476.
64. Booth CL, Garcia-Diaz AM, Youle MS, et al. Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J Antimicrob Chemother 2007; 59:517-524. Among recently diagnosed HIV-infected persons in London, 43.9% of new infections were from nonsubtype B HIV and the prevalence of antiretroviral drug resistance was 7.1% (8.2% among those recently HIV infected and 6.5% among those with established infection).
65. Bouchard M, Masquelier B, Moreno M, et al. HIV type 1 drug resistance among naive patients from Venezuela. AIDS Res Hum Retroviruses 2007; 23:482-485. This study demonstrated antiretroviral drug resistance in proviral DNA of clade B HIV isolated from asymptomatic, treatment-naïve individuals in Venezuela.
66. Oñoro MS, López MJP, Santana MAC, et al. Primary antiretroviral drug resistance among patients diagnosed with HIV infection in Gran Canaria (Spain) between 2002 and 2005. Enferm Infecc Microbiol Clin 2007; 25:437-440. This study demonstrated that among patients with a recent HIV diagnosis in Spain between 2002 and 2005, 12.8% had transmitted antiretroviral drug resistance and the frequency of drug resistance was higher among subtype B viruses, viruses from MSM, and viruses from patients infected in 2005.
67. Ríos M, Delgado E, Pérez-Alvarez L, et al. Antiretroviral drug resistance and phylogenetic diversity of HIV-1 in Chile. J Med Virol 2007; 79:647-656. Among 136 HIV-infected individuals from Chile, 49% receiving ART and 51% treatment naive, prevalence of antiretroviral drug resistance was demonstrated to be 77 and 2.5%, respectively. Additionally, phylogenetic analysis revealed the presence of BF intersubtype recombinants.
68. Ross L, Lim ML, Liao Q, et al. Prevalence of antiretroviral drug resistance and resistance associated mutations in antiretroviral therapy-naïve HIV-infected individuals from 40 United States cities. HIV Clin Trials 2007; 8:1-8. Using both phenotypic and genotypic resistance data, this study demonstrated 10% of HIV-infected treatment-naïve patients from 40 states in the United States were infected with resistant virus; drug resistance was more common in white than Hispanic or African-American individuals.
69. Sagir A, Oette M, Kaiser R, et al. Trends of prevalence of primary HIV drug resistance in Germany. J Antimicrob Chemother 2007; 60:843-848. Primary antiretroviral drug resistance in Germany was observed among 9% of treatment naïve, chronically infected individuals, and changes in drug resistance over time were associated with HIV subtypes other than B, in ethnic groups other than whites, and viruses isolated from risk groups other than MSM.
70. d'Aquin Toni T, Masquelier B, Minga A, et al. HIV-1 antiretroviral drug resistance in recently infected patients in Abidjan, Côte d'Ivoire: a 4-year survey, 2002-2006. AIDS Res Hum Retroviruses 2007; 23:1155-1160.
71. Chang SY, Chen MY, Lee CN, et al. Trends of antiretroviral drug resistance in treatment-naïve patients with human immunodeficiency virus type 1 infection in Taiwan. J Antimicrob Chemother 2008; 61:689-693. Trends in antiretroviral drug resistance in Taiwan from 1999 to 2006 were examined, revealing an overall increase in the prevalence of drug resistance to reverse transcriptase and protease inhibitors and a lower frequency of antiretroviral drug resistance among IDUs.
72. Vercauteren J, Derdelinckx I, Sasse A, et al. Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006. AIDS Res Hum Retroviruses 2008; 24:355-362. This study demonstrated a 9.5% prevalence of transmitted antiretroviral drug resistance in Belgium among samples collected between 2003 and 2006 and identified being infected in Belgium as the greatest risk factor for drug resistance.
73. de Ronde A, van Dooren M, de Rooij E, et al. Infection by zidovudine-resistant HIV-1 compromises the virological response to stavudine in a drug-naive patient. AIDS 2000; 14:2632-2633.
74. Violin M, Cozzi-Lepri A, Velleca R, et al. Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS 2004; 18:227-235.
75. Fox J, Dustan S, McClure M, et al. Transmitted drug-resistant HIV-1 in primary HIV-1 infection; incidence, evolution and impact on response to antiretroviral therapy. HIV Med 2008; 7:477-483.
76. Poggensee G, Kücherer C, Werning J, et al. Impact of transmission of drug-resistant HIV on the course of infection and the treatment success. Data from the German HIV-1 Seroconverter Study. HIV Med 2007; 8:511-519.
77. Imrie A, Carr A, Duncombe C, et al. Primary infection with zidovudine-resistant human immunodeficiency virus type 1 does not adversely affect outcome at 1 year. Sydney Primary HIV Infection Study Group. J Infect Dis 1996; 174:195-198.
78. Oette M, Kaiser R, Däumer M, et al. Primary HIV drug resistance and efficacy of firstline antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr 2006; 41:573-581.
79. Pillay D, Bhaskaran K, Jurriaans S, et al. The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS 2006; 20:21-28.
80. Taylor S, Cane P, Hué S, et al. Identification of a transmission chain of HIV type 1 containing drug resistance-associated mutations. AIDS Res Hum Retroviruses 2003; 19:353-361.
81. de Ronde A, van Dooren M, van Der Hoek L, et al. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J Virol 2001; 75:595-602.
82. Brenner BG, Routy JP, Petrella M, et al. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 2002; 76:1753-1761.
83. Gandhi RT, Wurcel A, Rosenberg ES, et al. Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis 2003; 37:1693-1698.
84. Brenner B, Routy JP, Quan Y, et al. Persistence of muttidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS 2004; 18:1653-1660.
85. Pao D, Andrady U, Clarke J, et al. Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr 2004; 37:1570-1573.
86. Delaugerre C, Morand-Joubert L, Chaix ML, et al. Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission. Antivir Ther 2004; 9:415-421.
87. Ghosn J, Pellegrin I, Goujard C, et al. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 2006; 20:159-170.
88. van Maarseveen NM, Wensing AMJ, de Jong D, et al. Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation. J Infect Dis 2007; 195:399-409.
89. Little SJ, Frost SDW, Wong JK, et al. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 2008; 82:5510-5518.
90. Doherty IA, Padian NS, Marlow C, Aral SO. Determinants and consequences of sexual networks as they affect the spread of sexually transmitted infections. J Infect Dis 2005; 191 (Suppl 1):S42-S54.
91. Liljeros F, Edling CR, Amaral LAN. Sexual networks: implications for the transmission of sexually transmitted infections. Microbes Infect 2003; 5:189-196.
92. Newman MEJ. The structure and function of complex networks. SIAM Rev 2003; 45:167-256.
93. Keeling MJ, Eames KTD. Networks and epidemic models. J R Soc Interface 2005; 2:295-307.
94. Ghani AC, lson CA, Ward H, et al. Sexual partner networks in the transmission of sexually transmitted diseases. An analysis of gonorrhea cases in Sheffield, UK. Sex Transm Dis 1996; 23:498-503.
95. Kretzschmar M, Morris M. Measures of concurrency in networks and the spread of infectious disease. Math Biosci 1996; 133:165-195.
96. Morris M. Sexual networks and HIV. AIDS 1997; 11:S209-S216.
97. Morris M, Kretzschmar M. Concurrent partnerships and the spread of HIV. AIDS 1997; 11:641-648.
98. Ghani AC, Garnett GP. Risks of acquiring and transmitting sexually transmitted diseases in sexual partner networks. Sex Transm Dis 2000; 27:579-587.
99. Kretzschmar M. Sexual network structure and sexually transmitted disease prevention: a modeling perspective. Sex Transm Dis 2000; 27:827-635.
100. Ghani AC, Donnelly CA, Garnett GP. Sampling biases and missing data in explorations of sexual partner networks for the spread of sexually transmitted diseases. Stat Med 1998; 17:2079-2097.
101. Boily MC, Poulin R, Masse B. Some methodological issues in the study of sexual networks: from model to data to model. Sex Transm Dis 2000; 27:558-571.
102. Pont FL, Blower SM. The supply and demand dynamics of sexual behavior: implications for heterosexual HIV epidemics. J Acquir Immune Defic Syndr 1991; 4:987-999.
103. Blower SM, van Griensven GJ. Effect of differential mortality on risk behavior change in cohort studies. J Acquir Immune Defic Syndr 1993; 6:1364-1367.
104. Robins G, Elliott P, Pattison P. Network models for social selection processes. Social Netw 2001; 21:1-30.
105. Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr 2005; 39:446-453.
106. Parsons JT, Schrimshaw EW, Wolitski RJ, et al. Sexual harm reduction practices of HIV seropositive gay and bisexual men: serosorting, strategic positioning, and withdrawal before ejaculation. AIDS 2005; 19 (Suppl 1):S13-S25.
107. Dukers NH, Goudsmit J, de Wit JB, et al. Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection. AIDS 2001; 15:369-378.
108. Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA 2004; 292:224-236.
109. Chesney MA, Barrett DC, Stall R. Histories of substance use and risk behavior: precursors to HIV seroconversion in homosexual men. Am J Public Health 1998; 88:113-116.
110. Weber AE, Craib KJ, Chan K, et al. Determinants of HIV serconversion in an era of increasing HIV infection among young gay and bisexual men. AIDS 2003; 17:774-777.
111. Plankey MW, Ostrow DG, Stall R, et al. The relationship between methamphetamine and popper use and risk of HIV seroconversion in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2007; 45: 85-92.
112. Burcham JL, Tindall B, Marmor M, et al. Incidence and risk factors for human immunodeficiency virus seroconversion in a cohort of Sydney homosexual men. Med J Aust 1989; 150:634-639.
113. Page-Shafer K, Veugelers PJ, Moss AR, et al. Sexual risk behavior and risk factors for HIV-1 seroconversion in homosexual men participating in the Tricontinental Seroconverter Study, 1982-1994. Am J Epidemiol 1997; 146:531-542.
114. Buchbinder SP, Vittinghoff E, Heagerty PJ, et al. Sexual risk, nitrite inhalant use, and lack of circumcision associated with HIV seroconversion in men who have sex with men in the United States. J Acquir Immune Defic Syndr 2005; 39:82-89.
115. Koblin BA, Husnik MJ, Colfax G, et al. Risk factors for HIV infection among men who have sex with men. AIDS 2006; 20:731-739.
116. Freeman EE, Weiss HA, Glynn JR, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and metaanalysis of longitudinal studies. AIDS 2006; 20:73-83.
117. Booth CL, Geretti AM. Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother 2007; 59:1047-1056.
118. Oette M, Kaiser R, Däumer M, et al. Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005. Dtsch Med Wochenschr 2007; 132:977-982. In this study, 11.9% of treatment-naïve HIV-infected individuals had antiviral drug resistance, which was not associated with age, ethnicity, sex, time since HIV diagnosis, transmission risk group, or viral subtype.
119. Palma AC, Araujo F, Duque V, et al. Molecular epidemiology and prevalence of drug resistance-associated mutations in newly diagnosed HIV-1 patients in Portugal. Infect Genet Evol 2007; 7:391-398. In this study of treatment-naïve HIV infected patients in Portugal, 7.7% had an antiretroviral drug-resistant virus; drug resistance was not associated with age, sex, route of transmission, or HIV subtype.
120. Yerly S, von Wyl V, Ledergerber B, et al. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS 2007; 21:2223-2229. This study demonstrates a stable rate of TDR among individuals with documented HIV-1 seroconversion in Switzerland between 1996 and 2005, and though no associations were observed between TDR and ethnicity, sex, or risk group, it was more commonly observed with subtype B HIV. This study is of particular interest due to the large sample size of the study (n = 822).
121. Yerly S, Vora S, Rizzardi P, et al. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS 2001; 15:2287-2292.
122. Wensing AMJ, van de Vijver DA, Angarano G, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192:958-966.
123. Colfax GN, Vittinghoff E, Grant R, et al. Frequent methamphetamine use is associated with primary nonnucleoside reverse transcriptase inhibitor resistance. AIDS 2007; 21:239-241. This was the first published study to demonstrate an association of transmitted resistance to NNRTIs with methamphetamine use in the previous month among MSM with recent HIV infection. The authors suggest that this association may be caused by methamphetamine- associated treatment interruptions among source partners.
124. Grossman Z, Lorber M, Maayan S, et al. Drug-resistant HIV infection among drug-naïve patients in Israel. Clin Infect Dis 2005; 40:294-302.
125. Gittens MV, Roth WW, Roach T, et al. The molecular epidemiology and drug resistance determination of HIV type 1 subtype B infection in Barbados. AIDS Res Hum Retroviruses 2003; 19:313-319.
126. Gorbach P, Drumright L, Javanbakht M, et al. Antiretroviral drug resistance and risk behavior among recently HIV-infected men who have sex with men. J Acquir Immune Defic Syndr 2008; 15;47:639-643. Among MSM with recent HIV infection, TDR was associated with use of methamphetamine and polydrug use. No other reported behaviors were associated with acquisition of drug-resistant HIV.
127. Drumright LN, Patterson TL, Strathdee SA. Club drugs as causal risk factors for HIV acquisition among men who have sex with men: a review. Subst Use Misuse 2006; 41:1551-1601.
128. Colfax G, Guzman R. Club drugs and HIV infection: a review. Clin Infect Dis 2006; 42:1463-1469.
129. Flaks RC, Burman WJ, Gourley PJ, et al. HIV transmission risk behavior and its relation to antiretroviral treatment adherence. Sex Transm Dis 2003; 30:399-404.
130. Reback CJ, Larkins S, Shoptaw S. Methamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual men. AIDS Care 2003; 15:775-785.
131. Leynaert B, Downs AM, de Vincenzi I. Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. European Study Group on Heterosexual Transmission of HIV. Am J Epidemiol 1998; 148:88-96.
132. Pilcher CD, Tien HC, Eron JJ, et al. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis 2004; 189:1785-1792.
133. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191:1403-1409.
134. Colfax GN, Buchbinder SP, Cornelisse PGA, et al. Sexual risk behaviors and implications for secondary HIV transmission during and after HIV seroconversion. AIDS 2002; 16:1529-1535.
135. Goudsmit J, Weverling GJ, van der Hoek L, et al. Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains. AIDS 2001; 15:2293-2301.
136. de Mendoza C, del Romero J, Rodríguez C, et al. Decline in the rate of genotypic resistance to antiretroviral drugs in recent HIV seroconverters in Madrid. AIDS 2002; 16:1830-1832.
137. Ammaranond P, Cunningham P, Oelrichs R, et al. No increase in protease resistance and a decrease in reverse transcriptase resistance mutations in primary HIV-1 infection: 1992-2001. AIDS 2003; 17:264-267.
138. Chaix ML, Descamps D, Harzic M, et al. Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS 2003; 17:2635-2643.
139. Bezemer D, Jurriaans S, Prins M, et al. Declining trend in transmission of drug-resistant HIV-1 in Amsterdam. AIDS 2004; 18:1571-1577.
140. U K Collaborative Group on HIV Drug Resistance and U K Collaborative HIV Cohort Study and U K Register of HIV Seroconverters. Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS 2007; 21:1035-1039. A total of 4454 samples from treatment-naïve patients between 1996 and 2004 were analyzed, including 316 from patients recently infected at the time of the resistance test. After an initial rise, TDR declined from a peak of around 14% in 2001-2002 to around 8% by the end of 2004, largely driven by a decrease in NRTI mutations.
141. Sánchez MS, Grant RM, Porco TC, et al. A decrease in drug resistance levels of the HIV epidemic can be bad news. Bull Math Biol 2005; 67:761-782.
142. Sánchez MS, Grant RM, Porco TC, Getz WM. HIV drug-resistant strains as epidemiologic sentinels. Emerg Infect Dis 2006; 12:191-197.
143. Porco TC, Martin JN, Page-Shafer KA, et al. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS 2004; 18:81-88.
144. Routy JP, Machouf N, Edwardes MD, et al. Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal. AIDS 2004; 18:2305-2312.
145. Lohse N, Obel N, Kronborg G, et al. Declining prevalence of HIV-infected individuals at risk of transmitting drug-resistant HIV in Denmark during 1997-2004. Antivir Ther 2006; 11:591-600.
146. de Mendoza C, Rodriguez C, Eiros JM, et al. Antiretroviral recommendations may influence the rate of transmission of drug-resistant HIV type 1. Clin Infect Dis 2005; 41:227-232.
147. de Mendoza C, Rodriguez C, García F, et al. Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance. J Antimicrob Chemother 2007; 59:698-704.
148. de Mendoza C, Jiménez-Nacher I, Garrido C, et al. Changing patterns in HIV reverse transcriptase resistance mutations after availability of
149. Brown AJL, Frost SDW, Mathews WC, et al. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis 2003; 187:683-686.
150. Yerly S, Jost S, Telenti A, et al. Infrequent transmission of HIV-1 drug-resistant variants. Antivir Ther 2004; 9:375-384.
151. de Mendoza C, Rodriguez C, Corral A, et al. Evidence for differences in the sexual transmission efficiency of HIV strains with distinct drug resistance genotypes. Clin Infect Dis 2004; 39:1231-1238.
152. Turner D, Brenner B, Routy JP, et al. Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infection. J Acquir Immune Defic Syndr 2004; 37:1627-1631.
153. Corvasce S, Violin M, Romano L, et al. Evidence of differential selection of HIV-1 variants carrying drug-resistant mutations in seroconverters. Antivir Ther 2006; 11:329-334.
154. Wahlberg J, Fiore J, Angarano G, et al. Apparent selection against transmission of zidovudine-resistant human immunodeficiency virus type 1 variants. J Infect Dis 1994; 169:611-614.
155. Colgrove RC, Pitt J, Chung PH, et al. Selective vertical transmission of HIV-1 antiretroviral resistance mutations. AIDS 1998; 12:2281-2288.
156. Simon V, Padte N, Murray D, et al. Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection. J Virol 2003; 77:7736-7745.
157. Rubio A, Leal M, Rey C, et al. Short-term evolution of HIV-1 viraemia and CD4+ cell counts in patients who have a primary mutation to zidovudine. AIDS 1998; 12:395-398.
158. Vanhems P, Gaudet R, Hirschel B, et al. Clinical features of acute HIV-1 infection: zidovudine-resistant isolates compared with zidovudine-sensitive isolates. AIDS 2000; 14:1065-1067.
159. Yirrell DL, Pickering H, Palmarini G, et al. Molecular epidemiological analysis of HIV in sexual networks in Uganda. AIDS 1998; 12:285-290.
160. Resik S, Lemey P, Ping LH, et al. Limitations to contact tracing and phylogenetic analysis in establishing HIV type 1 transmission networks in Cuba. AIDS Res Hum Retroviruses 2007; 23:347-356. In one of the few published studies that compared epidemiological linkage with phylogenetic analysis of HIV sequences, 27 out of 41 presumed transmission events were rejected by subtype mismatch or by phylogenetic tests or both. The authors suggest that long lags in time between the time of transmission and the time of sequence sampling, superinfection and incomplete epidemiological information may limit the concordance of phylogenetic reconstruction and reported epidemiological linkage.
161. Bao L, Vidal N, Fang H, et al. Molecular tracing of sexual HIV Type 1 transmission in the southwest border of China. AIDS Res Hum Retroviruses 2008; 24:733-742. This is the first report providing molecular epidemiological evidence of heterosexual transmission of HIV-1 in China's general population, which employs contact tracing with phylogenetic analysis of viral sequence data.
162. Pao D, Fisher M, Hué S, et al. Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. AIDS 2005; 19:85-90.
163. Lewis F, Hughes GJ, Rambaut A, et al. Episodic sexual transmission of HIV revealed by molecular phylodynamics. PLoS Med 2008; 5:e50. This study identified nine large clusters of related viruses from a small area of London spanning the period 1997-2003. Although no clustering by drug resistance was noted, the power to detect such clustering was low.
164. Gifford RJ, de Oliveira T, Rambaut A, et al. Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1. J Virol 2007; 81:13050-13056. The epidemiological characteristics of 5675 HIV-1 pol gene sequences sampled from distinct infections in the United Kingdom were analyzed in conjunction with 976 complete-genome and 3201 pol gene reference sequences sampled globally and representing the broad range of HIV-1 genetic diversity. Several Independent transmission chains within the United Kingdom were identified involving recently introduced strains, which indicated that strains more commonly associated with infections acquired heterosexually in East Africa are spreading among MSM. However, no clustering of drug-resistant viruses was observed.
165. Brenner BG, Roger M, Routy JP, et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 2007; 195:951-959. Among recently diagnosed and newly infected individuals with HIV in Quebec, TDR to NRTIs was significantly lower in clusters, with a trend toward a lower frequency of transmitted resistance to protease inhibitors in clusters; the frequency of transmitted resistance to NNRTIs was similar in clustered and nonclustered sequences. Age, viremia, and behavioral risk factors were similar for clustered and nonclustered sequences.
166. Drumright L, Little S, Richman D, Frost S. 14th Conference on Retroviruses and Opportunistic Infections [abstract 654]; 25-28 February 2007; Los Angeles, California.